Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study
Authors' conclusion
Life-years gained free of (recurrent) CVD by optimal CVRM and the addition of a GLP-1 RA or aSGLT-2i is dependent on baseline CVD status. These results aid individualizing prevention and promote shared decision-making in patients with T2D.
Study context
- Population
- Individuals with T2D from the CAPTURE study
- Participants
- 9,416 individuals
- Comparison
- Optimal cardiovascular risk management (CVRM) and addition of GLP-1 RA and SGLT2i; patients with vs without established cardiovascular disease (CVD)
- Primary endpoint
- Life-years free of (recurrent) CVD event gained with optimal CVRM and glucose-lowering agents with proven CV benefit
- Follow-up
- Lifetime
Methodological detailsnon-interventional, multinational, model-based estimation of lifetime benefit
- Non-interventional
- Multinational
- Model-based estimation of lifetime benefit
Primary result
As reported in the abstract
Lifetime benefit from optimal CVRM
Further findings
- Added lifetime benefit of GLP-1 RA plus SGLT2i in patients with CVD
- 1.2 · mean · SD 0.6 · years
Preventive medication use
- GLP-1 RA or SGLT2i use did not greatly differ by CVD history; BP-lowering drugs, statins and aspirin more frequent with CVD
Original publication
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study. Diabetes Obes Metab. Published 24 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →